- Global Pharma News & Resources

Biohaven Pharmaceuticals to Host Inaugural Research & Development Day on November 26, 2018

Biohaven Pharmaceuticals to Host Inaugural Research & Development Day on November 26, 2018 - Three panels with 13 KOLs highlighting migraine, glutamate and inflammation platforms

PR Newswire

NEW HAVEN, Conn., Nov. 20, 2018

NEW HAVEN, Conn., Nov. 20, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological diseases, today announced that it will host its inaugural Annual Research & Development Day on Monday, November 26, 2018 beginning at 10:30 a.m., Eastern Time in New York City. Members of Biohaven's senior management will be joined by expert key opinion leaders to hold discussions on the topics of Biohaven's three platforms: migraine (compounds BHV-3000 and BHV-3500), glutamate modulation (BHV-4157, BHV-5000), and inflammation/immune modifiers (BHV-3241 and pre-clinical programs). Panel discussions will feature the following experts:

Session moderated by Geoff Meacham, PhD, Managing Director, Senior Equity Analyst, Barclays 
Richard Lipton, MD, Albert Einstein College of Medicine
Andrew Blumenfeld, MD, Headache Center of Southern California
Jelena Pavlović, MD, PhD, Albert Einstein College of Medicine
Alexander Mauskop, MD, SUNY Downstate Medical Center and New York Headache Center


Session Moderated by Charles Duncan PhD, Managing Director, Senior Equity Analyst, Cantor Fitzgerald
John Krystal, MD, Yale University School of Medicine
Jeremy Schmahmann, MD, Harvard Medical School, Massachusetts General Hospital
Christopher Pittenger, MD, PhD, Yale University School of Medicine
Howard Feldman, MD, UCSD School of Medicine and Director of Alzheimer's Disease Cooperative Study
Sanjay Mathew, MD, Baylor College of Medicine
Michael Thase, MD, University of Pennsylvania, Perelman School of Medicine

Session moderated by Tyler Van Buren, Principal, Senior Equity Analyst, Piper Jaffray
Horacio Kaufmann, MD, NYU Langone Health, School of Medicine
Michael Lynes, PhD, University of Connecticut, Department of Molecular and Cellular Biology
David Spiegel, MD, PhD, Yale University School of Medicine and Department of Chemistry

Institutional investors and analysts may RSVP to
Interested parties may access the live video webcast of this presentation by visiting the Investors & Media section of Biohaven's website at A webcast replay of the presentation will be posted on the Biohaven website approximately two hours after the event.

About Biohaven
Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has combined internal development and research with intellectual property licensed from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, Rutgers, ALS Biopharma LLC and Massachusetts General Hospital. Currently, Biohaven's lead development programs include multiple compounds across its CGRP receptor antagonist, glutamate modulation, and myeloperoxidase inhibitor platforms. Biohaven's common shares are listed on the New York Stock Exchange and traded under the ticker symbol BHVN. More information about Biohaven is available at

Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release, including the Company's expectations for future growth and pipeline development, are forward-looking statements. You should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. Important factors to be considered in connection with forward-looking statements are described in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2018. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

For further information, contact Dr. Vlad Coric, the Chief Executive Officer at

View original content to download multimedia:

SOURCE Biohaven Pharmaceutical Holding Company Ltd.

Editor Details

Last Updated: 20-Nov-2018